Clinical Trial Update: An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia [Phase 3]

View source ↗

Summary

Open-label extension study of DS-5565 for 52 weeks in adults with pain associated with fibromyalgia completed; results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fibromyalgia

Drugs mentioned

• DS-5565 (DS-5565)

Snippet

Sponsor: Daiichi Sankyo | Conditions: Pain Associated With Fibromyalgia | Phase 3 | Status: COMPLETED | Results posted: 2020-07-23